Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

SIMPLE SUMMARY: REarranged during Transfection (RET) is an emerging target for several types of cancer, including non-small cell lung cancer (NSCLC). The recent U.S. FDA approval of pralsetinib and selpercatinib raises issues regarding the emergence of secondary mutations and amplifications involved...

Descripción completa

Detalles Bibliográficos
Autores principales: Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Brugia, Marco, Castiglione, Francesca, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961559/
https://www.ncbi.nlm.nih.gov/pubmed/33806299
http://dx.doi.org/10.3390/cancers13051091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961559/
https://www.ncbi.nlm.nih.gov/pubmed/33806299
http://dx.doi.org/10.3390/cancers13051091

Ejemplares similares